Idorsia Ltd. · SIX:IDIA
Idorsia — Fact Sheet (July 2026)
5 slides from Idorsia's fact sheet, Jul 29, 2026
Slide 1: Financial performance
Financial performance Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize
Slide 2: Financial results
Financial results Financial overview Net revenue of CHF 110 m in H1 2026 in CHF millions, except EPS (CHF) resulted from product sales (CHF 91 m), and number of shares (millions) First Half Second Quarter product sales to partners (CHF 6 m), and US GAAP results 2026 2025 2026 2025 contract revenues
Slide 3: Liquidity and indebtedness
The US GAAP net loss resulted in a net loss Liquidity and indebtedness per share of CHF (0.60) (basic and diluted) in the first half of 2026, compared to a net Liquidity on June 30, 2026, amounted to CHF 89 million. This amount does not include the income per share of CHF 0.26 basic and remaining CH
Slide 4: Idorsia Ltd – stock information
Idorsia Ltd – shares at a glance Idorsia Ltd – stock information As of June 30, 2026, the company has been Share price development (in CHF) notified of the following shareholdings amounting to 3% or more of the company’s — Idorsia Ltd 8 ordinary share capital: 7 6 Major shareholders* As of Jun 30, 2
Slide 5: About Idorsia and contact details
Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel,